Trade Aridis Pharmaceuticals, Inc. - ARDSus CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0059 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.2533 |
| Open | 0.294 |
| 1-Year Change | -72.26% |
| Day's Range | 0.2635 - 0.312 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 18, 2023 | 0.3090 | 0.0041 | 1.34% | 0.3049 | 0.3209 | 0.2601 |
| Jul 17, 2023 | 0.2533 | -0.0607 | -19.33% | 0.3140 | 0.3166 | 0.2491 |
| Jul 14, 2023 | 0.3153 | -0.0302 | -8.74% | 0.3455 | 0.3455 | 0.3090 |
| Jul 13, 2023 | 0.3490 | 0.0454 | 14.95% | 0.3036 | 0.3588 | 0.2790 |
| Jul 12, 2023 | 0.3289 | -0.0499 | -13.17% | 0.3788 | 0.3987 | 0.3153 |
| Jul 11, 2023 | 0.2606 | 0.0114 | 4.57% | 0.2492 | 0.2669 | 0.2490 |
| Jul 10, 2023 | 0.2617 | 0.0227 | 9.50% | 0.2390 | 0.2638 | 0.2390 |
| Jul 7, 2023 | 0.2491 | 0.0257 | 11.50% | 0.2234 | 0.2502 | 0.2234 |
| Jul 6, 2023 | 0.2263 | 0.0046 | 2.07% | 0.2217 | 0.2321 | 0.2213 |
| Jul 5, 2023 | 0.2272 | 0.0080 | 3.65% | 0.2192 | 0.2332 | 0.2192 |
| Jul 3, 2023 | 0.2148 | 0.0006 | 0.28% | 0.2142 | 0.2259 | 0.2142 |
| Jun 30, 2023 | 0.2144 | -0.0025 | -1.15% | 0.2169 | 0.2169 | 0.1993 |
| Jun 29, 2023 | 0.2129 | 0.0037 | 1.77% | 0.2092 | 0.2167 | 0.2092 |
| Jun 28, 2023 | 0.2116 | -0.0276 | -11.54% | 0.2392 | 0.2392 | 0.2092 |
| Jun 27, 2023 | 0.2413 | -0.0088 | -3.52% | 0.2501 | 0.2531 | 0.2345 |
| Jun 26, 2023 | 0.2492 | -0.0099 | -3.82% | 0.2591 | 0.2591 | 0.2491 |
| Jun 23, 2023 | 0.2597 | 0.0051 | 2.00% | 0.2546 | 0.2603 | 0.2492 |
| Jun 22, 2023 | 0.2566 | -0.0025 | -0.96% | 0.2591 | 0.2591 | 0.2541 |
| Jun 21, 2023 | 0.2565 | 0.0043 | 1.70% | 0.2522 | 0.2601 | 0.2501 |
| Jun 20, 2023 | 0.2552 | -0.0014 | -0.55% | 0.2566 | 0.2671 | 0.2516 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Aridis Pharmaceuticals, Inc. Company profile
About Aridis Pharmaceuticals Inc
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), cystic fibrosis and COVID-19. The Company's lead product candidate, AR-301, targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. Its clinical development activities are focused on AR-301, AR-712, and AR-501. Its development of antibody discovery and production platform technology called aPEXTM extends the capabilities of MabIgX, its differentiated antibody discovery platform.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Aridis Pharmaceuticals Inc revenues decreased 45% to $548K. Net loss applicable to common stockholders increased from $16.5M to $37.5M. Revenues reflect License revenue decrease of 87% to $131K. Higher net loss reflects Research and development - Balancing val increase from $12.3M to $28.9M (expense), General and administrative - Balancing increase of 11% to $4.1M (expense).
| Industry: | Bio Therapeutic Drugs |
983 University Avenue, Bldg. B
LOS GATOS
CALIFORNIA 95032
US
News
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com